Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in the Management of Ulcerative Colitis
NCT02516384Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2016
- Primary completion
- Dec 2016
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in ulcerative colitis (UC), sponsored by Weill Cornell Medicine. Primary endpoint: Safety post-FMT as determined by interview for adverse events at 36 months. Started Oct 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02516384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516384.